The Australian NSCLC market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Non-small cell lung cancer (NSCLC) is one of the types of Lung Cancer. About 80% to 85% of lung cancers are NSCLC. The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped as NSCLC because their treatment and prognoses (outlook) are often similar. Lung cancer begins when abnormal cells grow and multiply in an uncontrolled way in one or both lungs. Cancer that starts in the lungs is known as primary lung cancer. It can spread to other parts of the body such as the lymph nodes, brain, adrenal glands, liver, and bones. When cancer starts in another part of the body and spreads to the lungs, it is called secondary or metastatic cancer in the lung. This information is about primary lung cancer only.
An increasing number of diagnoses of non-small cell lung cancer and the increasing awareness in the countries of the developed and developing markets are also contributing towards the non-small cell lung cancer therapeutics market growth. This, coupled with increasing investments by major players in research and development activities, and the inclusion of non-small cell cancer therapeutics in pipelines of major market players are also boosting the market growth.
Some of the other factors which are also contributing to the non-small cell lung cancer therapeutics market growth are the increase in the proportion of the smoking population and exposure to toxins such as asbestos. Greater adoption and increasing demand for targeted therapies, which is considered to be the foundation of precision medicine due to the increasing R&D initiatives and also due to its sophistication in targeting cancerous cells, is one of the most prominent leading factors that are responsible for the growth.
NSCLC is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses. Lung cancer was the 5th most commonly diagnosed cancer in Australia in 2016.
In 2016, there were 10,261 new cases of NSCLC diagnosed in Australia (5,823 males and 4,437 females). In 2020, it is estimated that 11,136 new cases of lung cancer will be diagnosed in Australia (6,080 males and 5,056 females).
In 2018, there were 7,212 deaths from NSCLC in Australia (4,200 males and 3,012 females). In 2020, it is estimated that there will be 7,258 deaths (4,192 males and 3,066 females).
In 2012–2016, individuals diagnosed with NSCLC had a 19 % chance (16% for males and 22% for females) of surviving for five years compared to their counterparts in the general Australian population.
At the end of 2015, 6,363 people were living who had been diagnosed with lung cancer that year, 15,750 people living who had been diagnosed with NSCLC in the previous 5 years.